Cargando…

Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China

BACKGROUND: Bone metastasis has been suggested to be a significant impactor on the prognosis of newly diagnosed de novo metastatic hormone-sensitive prostate cancer (mHSPC), and some risk stratification models have been proposed on the basis of this hypothesis. However, the effectiveness of these ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yang, Ding, Li, Zheng, Yuxin, Wang, Kun, Xia, Wentao, Wang, Junqi, Ge, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825052/ https://www.ncbi.nlm.nih.gov/pubmed/36624752 http://dx.doi.org/10.7717/peerj.14500

Ejemplares similares

Development and validation of a novel risk model in newly diagnosed de novo bone metastatic prostate cancer (M1b): a retrospective study
por: Zhang, Yang, et al.
Publicado: (2023)

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification
por: Tian, Zijian, et al.
Publicado: (2021)

Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer
por: Basourakos, Spyridon P., et al.
Publicado: (2021)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3
por: Huang, Chen, et al.
Publicado: (2022)

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
por: Shiota, Masaki, et al.
Publicado: (2016)

Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men
por: Nakagawa, Ryunosuke, et al.
Publicado: (2022)

Multiparametric Prostate MRI in Biopsy-Naïve Men: A Prospective Evaluation of Performance and Biopsy Strategies
por: Krüger-Stokke, Brage, et al.
Publicado: (2021)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data
por: Tao, Tao, et al.
Publicado: (2022)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
por: Sigurdson, Samantha S., et al.
Publicado: (2020)

A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With de novo Distant Metastasis
por: Wang, Zheng, et al.
Publicado: (2020)

Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy
por: Ge, Qintao, et al.
Publicado: (2023)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
por: Sung, Winnie W. Y., et al.
Publicado: (2021)

Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4–20 ng/mL
por: Zheng, Yuxin, et al.
Publicado: (2022)

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
por: Vale, C L, et al.
Publicado: (2018)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
por: Sharova, Evgeniya, et al.
Publicado: (2021)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
por: Wang, Lei, et al.
Publicado: (2023)

Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer
por: Roy, Soumyajit, et al.
Publicado: (2023)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
por: Graff, Julie N., et al.
Publicado: (2020)

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
por: Wenzel, Mike, et al.
Publicado: (2021)

Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis
por: Chys, Brecht, et al.
Publicado: (2020)

TRPM8 protein expression in hormone naïve local and lymph node metastatic prostate cancer
por: Lunardi, Andrea, et al.
Publicado: (2021)

Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
por: Falagario, Ugo Giovanni, et al.
Publicado: (2021)

Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review
por: Wang, Yuhan, et al.
Publicado: (2020)

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer
por: Korček, Michal, et al.
Publicado: (2020)

Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients
por: Xie, Mu, et al.
Publicado: (2021)

External validation study of endometrial cancer preoperative risk stratification model (ENDORISK)
por: Vinklerová, Petra, et al.
Publicado: (2022)

Development and validation of a machine learning model for survival risk stratification after esophageal cancer surgery
por: Xu, Jinye, et al.
Publicado: (2022)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
por: Tagawa, Scott T., et al.
Publicado: (2013)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Outcomes of Older Men Receiving Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
por: Lage, Daniel E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k61unvu3dk2v7rkekb1l7tcgbk